Snow Canyon Therapeutics develops non-toxic therapies that restore redox homeostasis by targeting the NRF2 pathway to mitigate oxidative stress-related cellular damage. Their approach aims to reverse chronic diseases linked to dysregulated redox signaling, improving patients' quality of life through safer treatment options.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including metabolic and neurological disorders, have an oxidative etiology stemming from dysregulation of redox-sensitive signaling pathways. Current approaches to upregulate the NRF2 pathway, a key antioxidant defense mechanism, often rely on mild oxidants, leading to potential toxicity due to off-target oxidation.
Solution
Snow Canyon Therapeutics is developing non-toxic therapies designed to restore redox homeostasis by specifically targeting the NRF2 pathway. Their approach aims to mitigate oxidative stress-related cellular damage without the toxic side effects associated with traditional methods. By restoring proper cellular control of function, their medicines have the potential to reverse chronic diseases linked to dysregulated redox signaling and improve patients’ quality of life. The company's pre-clinical studies have validated the utility of their unique approach to treating redox-associated diseases.
Target Audience
The primary target audience includes patients suffering from chronic diseases with an oxidative etiology, as well as healthcare providers seeking safer and more effective treatment options.
Features
- Novel, non-toxic approach to restoring redox homeostasis
- Highly effective modulation of the NRF2 pathway
- Targeted mitigation of oxidative stress-related cellular damage
- Potential to reverse chronic diseases linked to dysregulated redox signaling
- Pre-clinical validation of therapeutic utility